ArticleFrontiers in microbiology2021
Tetrameric Neuraminidase of Influenza A Virus Is Required to Induce Protective Antibody Responses in Mice.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic Readiness.Vaccines · 2026Article
- Recombinant Tetrameric Neuraminidase Subunit Vaccine Provides Protection Against Swine Influenza A Virus Infection in Pigs.Vaccines · 2025Article
- Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.NPJ vaccines · 2024Article
- A human monoclonal antibody targeting the monomeric N6 neuraminidase confers protection against avian H5N6 influenza virus infection.Nature communications · 2024Article
- Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge.NPJ vaccines · 2024Article
- Advances in protein subunit vaccines against H1N1/09 influenza.Frontiers in immunology · 2024Review
- Targeting neuraminidase: the next frontier for broadly protective influenza vaccines.Trends in immunology · 2024Review
- A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses.NPJ vaccines · 2023Article
- Broadly Protective Neuraminidase-Based Influenza Vaccines and Monoclonal Antibodies: Target Epitopes and Mechanisms of Action.Viruses · 2023Review
- Production of Neuraminidase Virus Like Particles by Stably Transformed Insect Cells: A Simple Process for NA-Based Influenza Vaccine Development.Molecular biotechnology · 2022Article
- Article
- Prevalence and mechanisms of evolutionary contingency in human influenza H3N2 neuraminidase.Nature communications · 2022Article
- Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.Frontiers in immunology · 2022Review
- Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza neuraminidase (NA) is able to induce cross-subtype immunity and is considered as a promising target for the development of universal influenza vaccines. However, commercial influenza vaccines only induced low NA-specific immune responses due to the low amounts and the denatured conformation of NA proteins in current inactivated or split influenza vaccines. Here we investigated the protective efficacy of recombinant tetrameric and monomeric NA proteins to determine whether the conformation contributed to induce protective immunity. We found that H1N1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.